Rituximab maintenance therapy for the treatment and management of rheumatoid arthritis : a review of clinical effectiveness / Kavita Singh, Suzanne McCormack
The coverage of rituximab, under the various government-sponsored drug plans, includes a maximum of two courses per year; rituximab is not currently reimbursed for maintenance treatment. In 2007, the Canadian Agency for Drugs and Technologies in Health reviewed rituximab under the Common Drug Review. Rituximab was given a positive recommendation, however the Committee noted that the evidence for repeated doses was insufficient and that retreatment should be considered only in patients who achieved a response followed by a loss of effect. Clinicians would like to prescribe rituximab to patients, prior to a flare or loss of effect. Therefore, a review of the evidence is needed to support the administration of rituximab as regularly scheduled therapy to maintain remission or low disease activity in patients with moderate to severe rheumatoid arthritis..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
July 04, 2018 |
|---|---|
| Erschienen: |
Ottawa: CADTH ; July 04, 2018 |
| Ausgabe: |
Version 1.0. |
| Reihe: |
CADTH rapid response report: summary with critical appraisal |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, Kavita [VerfasserIn] |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Administration, Intravenous |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed April 9, 2019) |
|---|
| Umfang: |
1 online resource (1 PDF file (19 pages)) ; illustrations. |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1773194372 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1773194372 | ||
| 003 | DE-627 | ||
| 005 | 20230428012019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2018 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1773194372 | ||
| 035 | |a (DE-599)KEP068700466 | ||
| 035 | |a (NCBI)1743199 | ||
| 035 | |a (EBP)068700466 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, Kavita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab maintenance therapy for the treatment and management of rheumatoid arthritis |b a review of clinical effectiveness |c Kavita Singh, Suzanne McCormack |
| 250 | |a Version 1.0. | ||
| 264 | 1 | |a Ottawa |b CADTH |c July 04, 2018 | |
| 300 | |a 1 online resource (1 PDF file (19 pages)) |b illustrations. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH rapid response report: summary with critical appraisal | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed April 9, 2019) | ||
| 520 | |a The coverage of rituximab, under the various government-sponsored drug plans, includes a maximum of two courses per year; rituximab is not currently reimbursed for maintenance treatment. In 2007, the Canadian Agency for Drugs and Technologies in Health reviewed rituximab under the Common Drug Review. Rituximab was given a positive recommendation, however the Committee noted that the evidence for repeated doses was insufficient and that retreatment should be considered only in patients who achieved a response followed by a loss of effect. Clinicians would like to prescribe rituximab to patients, prior to a flare or loss of effect. Therefore, a review of the evidence is needed to support the administration of rituximab as regularly scheduled therapy to maintain remission or low disease activity in patients with moderate to severe rheumatoid arthritis. | ||
| 650 | 2 | |a Arthritis, Rheumatoid |x drug therapy |0 https://id.nlm.nih.gov/mesh/D001172Q000188 | |
| 650 | 2 | |a Rituximab |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D000069283Q000627 | |
| 650 | 2 | |a Antirheumatic Agents |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D018501Q000627 | |
| 650 | 2 | |a Administration, Intravenous |0 https://id.nlm.nih.gov/mesh/D061605 | |
| 650 | 2 | |a Treatment Outcome |0 https://id.nlm.nih.gov/mesh/D016896 | |
| 651 | 2 | |a Canada |0 https://id.nlm.nih.gov/mesh/D002170 | |
| 655 | 2 | |a Review |0 https://id.nlm.nih.gov/mesh/D016454 | |
| 700 | 1 | |a McCormack, Suzanne |e verfasserin |4 aut | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK537725/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994091225 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994017505 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999794089 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995685005 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987684291 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987771631 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK537725/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK537725/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK537725/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK537725/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK537725/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||